News
Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback